Ovarian Cancer

(Last 5 years)

  1. Janda, M., Youlden, D.R., Baade, P.D., Jackson, D., and Obermair A. Elderly patients with stage III or IV ovarian cancer: should they receive standard care?, Int J Gynecol Cancer, 18(5): Sep-Oct. 2008: 896-907.
  2. Obermair A, Hiebl S. Laparoscopy in the treatment of ovarian tumours of low malignant potential. Aust N Z J Obstet Gynaecol. 2007 Dec;47(6):438-44.
  3. Obermair A, Fuller A, Lopez-Varela E, van Gorp T, Vergote I, Eaton L, FowlerJ, Quinn M, Hammond I, Marsden D, Proietto A, Carter J, Davy M, Tripcony L, Abu-Rustum N. A new prognostic model for FIGO stage 1 epithelial ovarian cancer. Gynecol Oncol. 2007 Mar;104(3):607-11.
  4. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, Proietto A, Davy M, Carter J, Nicklin J, Perrin L, Obermair A. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005 Sep 1;23(25):5938-42.
  5. Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer. 2003 May;39(8):1129-40. Erratum in: Eur J Cancer. 2004 Mar;40(4):627.
  6. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JC, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PD, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G; Australian Cancer Study; Australian Ovarian Cancer Study Group. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer. 2009 Jan 27;100(2):412-20.
  7. Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. 
  8. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC; Australian Cancer Study Group; Australian Ovarian Cancer Study Group. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer. 2008 Nov;44(16):2477-84.
  9. Olsen CM, Nagle CM, Whiteman DC, Purdie DM, Green AC, Webb PM; Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group. Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int J Cancer. 2008 Jul 15;123(2):450-6.
  10. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL; Ovarian Cancer Association Consortium. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer. 2008 Jul 15;123(2):380-8.